Sign in
Taking people in United StatesNo phase

Registry following people with Wolfram syndrome and related WFS1 disorders

Collects health history and genetic testing from people with Wolfram syndrome and their families.

Key facts

Who runs it
Washington University School of Medicine
Where
St Louis, United StatesSee the site
Trial code
Registry title
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Status
Recruiting
People taking part
5,000 people, planned
Started
Jul 2011
Expected to end
Apr 2027
Type of study
Observational
Record updated
23 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people of any age with Wolfram syndrome. Unaffected parents, brothers, sisters and spouses can join as controls.

Age
From birth (0 Years); no upper age limit is given. Children can join.
Sex
All sexes can join.
Disease stage
A diagnosis of Wolfram syndrome. This means 2 major signs (diabetes mellitus before age 16, optic atrophy before age 16), or 1 major sign plus 2 minor signs, or 2 disease-causing WFS1 or CISD2 gene changes.
Biomarker or test result
Minor signs include 1 loss of function mutation in WFS1/CISD2 or a family history of Wolfram syndrome. Two disease-causing WFS1 or CISD2 mutations are enough on their own. Blood for WFS1 gene testing is taken if not already done.

Main reasons for not taking part

  • Cannot get help with translation, so cannot understand the questionnaire
  • Unaffected family members who cannot understand the Informed Consent Document

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Major Criteria
  • Diabetes mellitus <16 yrs
  • Optic atrophy <16 yrs; Minor Criteria
  • Diabetes insipidus
  • Diabetes mellitus >16yrs
  • Optic atrophy >16 yrs
  • Sensorineural deafness
  • Neurological signs (ataxia, epilepsy, cognitive impairment)
  • Renal tract abnormalities (structural or functional)
  • 1 loss of function mutation in WFS1/CISD2 AND/OR family history of Wolfram syndrome; Minimum Required
  • 2 major OR
  • 1 major plus 2 minor criteria OR
  • 2 pathological WFS1 or CISD2 mutations are identified; Other variable suggestive evidence
  • Hypogonadism (males)
  • An absence of type 1 diabetes auto-antibodies
  • Bilateral cataracts
  • Psychiatric disorder
  • Gastrointestinal

Who cannot take part

  • Inability of a patient and/or a guardian to obtain help with translation and thus, inability to understand questionnaire
  • Parent, Sibs, and Spouses:
  • Parents, sibs, and spouses that are unaffected will be recruited as controls. Inclusion criterion is having the unaffected status and exclusion criterion is if the person cannot understand the Informed Consent Document

Other criteria

  • Any patient worldwide with a diagnosis of Wolfram syndrome and with access to the Internet can be enrolled in the Registry. Since the disease usually manifests in the first decade of life and tends to have an inevitably progressive course, participation of minors is important for establishing the natural course of the disease

Where in United States

  • Washington University School of MedicineSt Louis, United StatesContact: Fumihiko Urano, MDTaking people

About the trial

What the trial wants to find out

In this study, the investigators hypothesize that studying monogenic variants with strong effect associated with severe insulin deficiency of Wolfram syndrome will provide important insights into the more complex type 1 and type 2 diabetes mellitus.

Read full original descriptionShow less

Aim 1. Establish and maintain a registry of patients with Wolfram syndrome. An Internet based registry will be employed to enroll participants with the clinical diagnosis of Wolfram syndrome (insulin dependent DM and bilateral OA). Clinical information regarding age of diagnosis and progression of the disease will be collated and analyzed to better define its natural history, along with potential metabolic phenotypes such as glucose intolerance of heterozygous parents and unaffected sibs.

If not already completed, blood for WFS1 sequence analysis will be obtained on the participants (parents and sibs also for control purposes) and sent to a CLIA certified lab to define the mutation. This information will benefit patient families and referring physicians by providing a genetic diagnosis and where indicated. The Wolfram Syndrome Registry will foster international collaborations to more efficiently and systematically collect Wolfram syndrome patients and their clinical and experimental data.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Plain-language title
Registry following people with Wolfram syndrome and related WFS1 disordersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
23 December 2025